Artificial intelligence (AI)-based drug developer Recursion has dosed the first patient in its Phase II ALDER trial (NCT06536465) assessing its first new chemical entity to be developed through its ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement. The ...

This biotech could still be a long way from having a drug on the market in 2026. But at the moment, it's burning cash like wild, and there's no sign of when that'll end, as it has nothing in the way ...